Datapoint: AbbVie’s Elahere Gains Full FDA Approval in Ovarian Cancer

The FDA last week granted full approval to AbbVie’s Elahere (mirvetuximab soravtansine-gynx) in certain ovarian cancer patients that have received up to three prior therapies. The antibody-drug conjugate received accelerated approval in November 2022. Phase 3 trial data for Elahere showed that the drug reduced the overall risk of cancer progression by 35%, leading to its full approval. Elahere currently holds covered or better status for 58% of all insured lives under the medical benefit.

SOURCE: MMIT Analytics, as of 3/27/24

0

0

0 Comments

0

0

• Datapoint